Show simple item record

dc.contributor.authorGrønhøj, C
dc.contributor.authorJensen, DH
dc.contributor.authorDehlendorff, C
dc.contributor.authorMarklund, L
dc.contributor.authorWagner, S
dc.contributor.authorMehanna, H
dc.contributor.authorMunck-Wikland, E
dc.contributor.authorRamqvist, T
dc.contributor.authorNäsman, A
dc.contributor.authorWittekindt, C
dc.contributor.authorWürdemann, N
dc.contributor.authorSharma, SJ
dc.contributor.authorGattenlöhner, S
dc.contributor.authorKiss, K
dc.contributor.authorAndersen, E
dc.contributor.authorSpruce, R
dc.contributor.authorBatis, N
dc.contributor.authorRobinson, M
dc.contributor.authorHarrington, K
dc.contributor.authorWinter, S
dc.contributor.authorJones, TM
dc.contributor.authorKlussmann, JP
dc.contributor.authorDalianis, T
dc.contributor.authorFriborg, J
dc.contributor.authorvon Buchwald, C
dc.date.accessioned2019-01-25T09:35:42Z
dc.date.issued2018-06-01
dc.identifier.citationBritish journal of cancer, 2018, 118 (12), pp. 1672 - 1681
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3021
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-018-0107-9
dc.description.abstractBACKGROUND: The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could lead to misallocation of patients. We established nomograms for overall survival (OS) and progression-free survival (PFS) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and known HPV-DNA and p16 status, and validated the models in cohorts from high- and low-prevalent HPV countries. METHODS: Consecutive OPSCC patients treated in Denmark, 2000-2014 formed the development cohort. The validation cohorts were from Sweden, Germany, and the United Kingdom. We developed nomograms by applying a backward-selection procedure for selection of variables, and assessed model performance. RESULTS: In the development cohort, 1313 patients, and in the validation cohorts, 344 German, 503 Swedish and 463 British patients were included. For the OS nomogram, age, gender, combined HPV-DNA and p16 status, smoking, T-, N-, and M-status and UICC-8 staging were selected, and for the PFS nomogram the same variables except UICC-8 staging. The nomograms performed well in discrimination and calibration. CONCLUSIONS: Our nomograms are reliable prognostic methods in patients with OPSCC. Combining HPV DNA and p16 is essential for correct prognostication. The nomograms are available at www.orograms.org .
dc.formatPrint-Electronic
dc.format.extent1672 - 1681
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectPapillomaviridae
dc.subjectOropharyngeal Neoplasms
dc.subjectDNA, Viral
dc.subjectNomograms
dc.subjectCohort Studies
dc.subjectReproducibility of Results
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectGermany
dc.subjectDenmark
dc.subjectSweden
dc.subjectFemale
dc.subjectMale
dc.subjectUnited Kingdom
dc.subjectSquamous Cell Carcinoma of Head and Neck
dc.titleDevelopment and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams).
dc.typeJournal Article
dcterms.dateAccepted2018-04-12
rioxxterms.versionofrecord10.1038/s41416-018-0107-9
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume118
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record